Analgesics Market Report 2024 (Global Edition)

Global Analgesics Market Report 2024 Market Size Split by Type (Prescription, Over-the-counter (OTC))), by Drug Class (Opioids, NSAIDs), by Route of Administration (Oral, Injectables), by Pain type (M...

Analgesics Market Report Description

We have various report editions of Analgesics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape: Analgesic Market

Leading pharmaceutical firms like Pfizer, Johnson & Johnson, and GlaxoSmithKline dominate the fiercely competitive analgesics business. These businesses make significant R&D investments to create novel and potent painkiller formulations, such as sophisticated medication delivery methods and non-opioid substitutes. Generic medicine makers are a major competitor in the market as they provide less expensive options to name-brand drugs. Furthermore, up-and-coming companies that specialize in herbal and natural analgesics are becoming more popular. The analgesics industry is becoming more competitive because of the prevalence of strategic alliances, mergers, and acquisitions among firms looking to broaden their product offerings and increase their market share. 
•    For instance, in January 2024, Sun Pharma entered into a definitive merger with TARO Pharmaceutical, specializing in generic dermatology analgesics. Through this merger, the two companies would utilize their combined capabilities to develop enhanced patient care therapies for the U.S. market.
(Source:https://sunpharma.com/wp-content/uploads/2024/01/1-17-24-Sun-Taro-Joint-Press-Release-Final-for-Release-with-BoA-changes.pdf )

Top Companies Market Share in Analgesics Industry: (In no particular order of Rank)

• Crown Pharmaceuticals
• Perrigo Company
• A&S Pharmaceutical Corp
• LNK International
• Medipaams India
• SRS Pharmaceuticals
• Umang Pharma
• YaoPharma
• Farmson
• Bayer
• Pizer
• McNeil
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which Region will dominate the Market in 2024?

North America garnered a major share in the analgesics market in 2024 and is expected to continue to dominate during the forecast period, due to a rise in the market for non-opioid medications, the presence of important figures, and advancements in R&D in the area's healthcare industry. Both prescription and over-the-counter analgesics are readily available in the area because of a robust regulatory system. Furthermore, the continued opioid epidemic has accelerated the creation and use of non-opioid options for pain management. The dominance of North America in the analgesics industry is further supported by the existence of significant pharmaceutical firms and ongoing research and development initiatives. The main competitors in the U.S. market are engaged in a moderate amount of merger and acquisition (M&A) activity. These tactics are used by many market participants to increase their customers. The FDA oversees the requirements for labeling, pre-market clearance or approval, and GMP standards for production, with a focus on safety and efficacy. Furthermore, producers must notify the FDA of any unfavorable product occurrences, and the agency may take regulatory action if safety issues are raised.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to register the highest CAGR of xx% from 2024 to 2031, due to a rise in the usage of painkillers, increased knowledge of the use of analgesic medications, growth in healthcare spending, a rise in the market for over-the-counter analgesics, and a rise in the use of analgesic products. Numerous variables, including a sizable population base, growing knowledge of pain treatment, increased disposable income, and improved healthcare infrastructure, are responsible for the region's rapid rise. The need for analgesics in the area is driven by the aging population in nations like China and Japan as well as the increased incidence of chronic pain problems. The rapid expansion of the Asia-Pacific analgesics market is also attributed to the growing pharmaceutical sector, rising healthcare costs, and the uptake of cutting-edge pain management treatments. 

The current report Scope analyzes Analgesics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

Analgesics Market Analysis

Analgesics Market Type Segment Analysis

• Prescription
• Over-the-counter (OTC)

Based on the type the market is segmented into prescription drugs and OTC drugs. Among these OTC drugs dominates the market and highest revenue in 2024. OTC pain relievers are becoming more and more popular for self-medication because of their simple availability and the growth of online shopping. These over-the-counter choices provide easy pain treatment for a range of ailments. They include paracetamol, nonsteroidal anti-inflammatory medications (NSAIDs), and combination products. OTC analgesics are widely used since they are more convenient to buy thanks to the growth of internet pharmacies. The market for over-the-counter analgesics is expanding because customers can successfully and quickly control their pain thanks to their availability without a prescription. 
•    For instance, in February 2020, GlaxoSmithKline received US FDA approval for Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID) as an OTC product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, and ankle, or knee in adults above 18 years of age.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Analgesics Industry. Request a Free Sample PDF!

Analgesics Market Drug Class Segment Analysis

• Opioids
• NSAIDs

By drug class, the non-opioid drugs segment was the major contributor in 2024 and is expected to maintain its lead during the forecast period, because non-opioid analgesics are widely used to relieve pain and have fewer side effects. Additionally, government and commercial organizations have taken steps to promote the use of non-opioid medications as painkillers. However, because opioids have analgesic, anti-inflammatory, and antipyretic properties, the opioid medicine market is anticipated to rise significantly throughout the projected period. The rise of the opioid segment is also anticipated to be driven by an increase in the prevalence of chronic illnesses including cancer, cardiovascular disease, TB, and arthritis throughout the projected period.
•    For instance, In July 2023, Motive Health, launched its Motive Knee, a muscle stimulation device approved by the US Food and Drug Administration (FDA) in the U.S. This provides a non-invasive, non-opioid alternative for managing arthritis-induced knee discomfort.
(Source:https://www.medicaldevice-network.com/projects/motive-knee-muscle-stimulation-device-usa/#:~:text=Developed%20by%20Motive%20Health%2C%20a,first%2090%20days%20of%20use. )

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Analgesics Route of Administration Segment Analysis

Based on the route of administration, the oral administration segment dominated the market in 2024, and this trend is expected to continue during the analgesics market forecast period because oral analgesic administration is a straightforward, non-invasive method of administering painkillers that is also more effective than other methods. Furthermore, the expansion of the oral administration segment is driven by improvements in R&D efforts in the pharmaceutical sectors and an increase in the number of medication approvals by the U.S. FDA. Important elements influencing the sector share include the ease with which analgesic preparation may be administered orally and its non-invasive character.
•    For instance, Glenmark Pharmaceuticals obtained USFDA approval for its generic Acetaminophen and Ibuprofen tablets. The company's drug, a generic version of Advil 2 Dual Action, will be distributed in the US market by Glenmark Therapeutics Inc, USA.
(Source:https://www.business-standard.com/companies/news/glenmark-pharma-receives-usfda-nod-for-generic-anti-inflammatory-drug-124042900171_1.html )
•    For instance, in January 2023, Yaral Pharma Inc. launched a diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma's Flector (diclofenac epolamine) topical system in the United States. These authorized generics are poised to rapidly expand their product line and will likely have significant market growth in the region.
(Source:https://www.empr.com/home/news/diclofenac-epolamine-topical-system-a-generic-of-flector-now-available/ )

• Oral
• Injectables

Analgesics Pain type Segment Analysis

Based on the pain type the market is segmented into musculoskeletal, surgical and trauma, cancer, neuropathic, migraine, obstetrical, fibromyalgia, pain due to burns, dental/facial, and pediatric. Musculoskeletal pain management exhibits a clear dominance in the analgesics market due to the high prevalence of conditions such as arthritis, back pain, and sports injuries. The aging population and those who lead active lifestyles are more likely to suffer from these disorders, which increases the demand for efficient pain management. Musculoskeletal pain is widely treated with both prescription and over-the-counter analgesics, making it a vital market niche. This dominance is further reinforced by the continuous research and development aimed at enhancing medication formulations and focusing on certain pain pathways. Sustained growth in this market is also attributed to the rise in sedentary lifestyles and growing knowledge of pain treatment choices. 
•    For instance, in June 2023 according to data published by CDC, about 1 in 5 adults in the U.S., totaling around 53.2 million individuals, are affected by some form of arthritis. Among the various types of arthritis, osteoarthritis (OA) is the most commonly diagnosed arthritis, accounting for more than 32.5 million individuals in the country.

• Musculoskeletal
• Surgical and Trauma
• Cancer
• Neuropathic
• Migraine
• Obstetrical
• Fibromyalgia
• Pain due to Burns
• Dental/Facial
• Pediatric

Analgesics Application Segment Analysis

Based on the application the market is segmented into internal and external applications. Among these internal applications dominate the market. Oral and injectable analgesics are used internally to treat pain originating from within the body. This group includes injectables (intravenous and intramuscular) and oral drugs (tablets, capsules, and liquid formulations). Many different types of pain can be effectively treated with internal analgesics, such as severe acute pain, post-operative pain, and chronic pain. Internal applications represent a sizable portion of the analgesics industry due to their affordability and effectiveness in delivering systemic relief.

• Internal
• External

Analgesics Distribution Channel Segment Analysis

The retail pharmacies segment dominated the analgesics market, with a revenue share of xx% in 2024. The increasing availability of over-the-counter (OTC) prescriptions, the high rate of generic penetration, and the rising number of prescriptions for analgesics due to the rising incidence rate of pain, accidents, etc. are all factors contributing to the expansion of the retail pharmacy market. Another element driving the segment's rise is the increase in over-the-counter medicine releases. For example, analgesics like ketorolac, ibuprofen, and diclofenac have lately been available over the counter.

• Retail Pharmacies
• Online Pharmacies

Author's Detail

Vinayak Bali

Senior Research Analyst at Cognitive Market Research

LinkedIn

Profile

Catering to tailored needs of clients in Consulting, Business Intelligence, Market Research, Forecasting, Matrix-Modelling, Data Analytics, Competitive Intelligence, Primary research and Consumer Insights.

Author's Conclusion